28896 Competitors

28896 (CNSX:BAMM) and RIV Capital (TSE:RIV) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Ratings

This is a breakdown of current recommendations and price targets for 28896 and RIV Capital, as provided by MarketBeat.com.

RIV Capital has a consensus target price of C$4.00, indicating a potential upside of 96.08%.

Valuation & Earnings

This table compares 28896 and RIV Capital's revenue, earnings per share and valuation.

28896 has higher earnings, but lower revenue than RIV Capital.

Profitability

This table compares 28896 and RIV Capital's net margins, return on equity and return on assets.

Summary

RIV Capital beats 28896 on 1 of the 1 factors compared between the two stocks.

28896 (CNSX:BAMM) and Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk.

Profitability

This table compares 28896 and Willow Biosciences Inc. (WLLW.TO)'s net margins, return on equity and return on assets.

Earnings & Valuation

This table compares 28896 and Willow Biosciences Inc. (WLLW.TO)'s top-line revenue, earnings per share and valuation.

28896 has higher earnings, but lower revenue than Willow Biosciences Inc. (WLLW.TO).

Analyst Ratings

This is a breakdown of recent ratings for 28896 and Willow Biosciences Inc. (WLLW.TO), as reported by MarketBeat.

Willow Biosciences Inc. (WLLW.TO) has a consensus price target of C$2.25, suggesting a potential upside of 75.78%.

Summary

Willow Biosciences Inc. (WLLW.TO) beats 28896 on 1 of the 1 factors compared between the two stocks.

MediPharm Labs (TSE:LABS) and 28896 (CNSX:BAMM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Valuation and Earnings

This table compares MediPharm Labs and 28896's top-line revenue, earnings per share (EPS) and valuation.

28896 has lower revenue, but higher earnings than MediPharm Labs.

Profitability

This table compares MediPharm Labs and 28896's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings for MediPharm Labs and 28896, as reported by MarketBeat.com.

MediPharm Labs presently has a consensus target price of C$1.53, suggesting a potential upside of 229.03%.

Summary

MediPharm Labs beats 28896 on 2 of the 2 factors compared between the two stocks.

Khiron Life Sciences (CVE:KHRN) and 28896 (CNSX:BAMM) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Khiron Life Sciences and 28896, as provided by MarketBeat.com.

Khiron Life Sciences presently has a consensus target price of C$1.20, indicating a potential upside of 135.29%.

Profitability

This table compares Khiron Life Sciences and 28896's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Khiron Life Sciences and 28896's gross revenue, earnings per share and valuation.

28896 has lower revenue, but higher earnings than Khiron Life Sciences.

Summary

Khiron Life Sciences beats 28896 on 1 of the 1 factors compared between the two stocks.

28896 (CNSX:BAMM) and Delta 9 Cannabis (TSE:DN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for 28896 and Delta 9 Cannabis, as provided by MarketBeat.com.

Delta 9 Cannabis has a consensus target price of C$1.10, indicating a potential upside of 89.66%.

Earnings & Valuation

This table compares 28896 and Delta 9 Cannabis' top-line revenue, earnings per share and valuation.

28896 has higher earnings, but lower revenue than Delta 9 Cannabis.

Profitability

This table compares 28896 and Delta 9 Cannabis' net margins, return on equity and return on assets.

Summary

Delta 9 Cannabis beats 28896 on 2 of the 2 factors compared between the two stocks.

Meta Growth (CVE:META) and 28896 (CNSX:BAMM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Earnings and Valuation

This table compares Meta Growth and 28896's revenue, earnings per share and valuation.

28896 has lower revenue, but higher earnings than Meta Growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Meta Growth and 28896, as provided by MarketBeat.

Profitability

This table compares Meta Growth and 28896's net margins, return on equity and return on assets.

Summary

Meta Growth beats 28896 on 1 of the 1 factors compared between the two stocks.